Living Cell-Target Responsive Accessibility Profiling Reveals Silibinin Targeting ACSL4 for Combating Ferroptosis.
Sign Up to like & getrecommendations! Published in 2022 at "Analytical chemistry"
DOI: 10.1021/acs.analchem.2c03515
Abstract: We report a living cell-target responsive accessibility profiling (LC-TRAP) approach to identify the targetome of silibinin (SIL), a well-established hepatoprotective natural product (NP), in HepG2 cells. Proteins showing accessibility changes, probed by covalent lysine labeling… read more here.
Keywords: living cell; cell target; accessibility; ferroptosis ... See more keywords
Immunology: The patterns of T-cell target recognition
Sign Up to like & getrecommendations! Published in 2017 at "Nature"
DOI: 10.1038/nature23091
Abstract: The binding of T-cell receptors to peptide molecules not normally present in the body can trigger an immune response. Predicting which peptide a T-cell receptor will bind to — a difficult feat — has now… read more here.
Keywords: patterns cell; immunology patterns; target recognition; cell target ... See more keywords
Phosphoinositide 3‐kinase δ is a regulatory T‐cell target in cancer immunotherapy
Sign Up to like & getrecommendations! Published in 2019 at "Immunology"
DOI: 10.1111/imm.13082
Abstract: Tumour infiltration by regulatory T (Treg) cells contributes to suppression of the anti‐tumour immune response, which limits the efficacy of immune‐mediated cancer therapies. The phosphoinositide 3‐kinase (PI3K) pathway has key roles in mediating the function… read more here.
Keywords: regulatory cell; kinase regulatory; phosphoinositide kinase; cell target ... See more keywords
Cell-Target-Specific Anti-Inflammatory Effect of Empagliflozin: In Vitro Evidence in Human Cardiomyocytes
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Molecular Biosciences"
DOI: 10.3389/fmolb.2022.879522
Abstract: The antidiabetic sodium–glucose cotransporter type 2 inhibitor (SGLT2i) empagliflozin efficiently reduces heart failure (HF) hospitalization and cardiovascular death in type 2 diabetes (T2D). Empagliflozin-cardioprotection likely includes anti-inflammatory effects, regardless glucose lowering, but the underlying mechanisms… read more here.
Keywords: empagliflozin; cell target; human cardiomyocytes; anti inflammatory ... See more keywords